No Data
No Data
No Data
No Data
No Data
Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials
Canbridge Pharmaceuticals (HKG:1228) announced that it would discontinue the development of its new glioblastoma multiforme drug CAN008 after Phase II clinical trials, according to a Monday filing on
MT NewswiresApr 23 10:42
Beihai Kangcheng-B (01228.HK) decided to discontinue development and further testing of CAN008 in the field of glioblastoma
Beihai Kangcheng-B (01228.HK) announced that according to top-line data from the CAN008 phase II clinical trial for newly diagnosed glioblastoma patients, CAN008 provided no additional benefit compared to placebo in terms of progression-free survival or overall survival in patients receiving standard treatment with temozolomide and radiotherapy.
Zhitong FinanceApr 22 22:58
Beihai Kangcheng-B (01228.HK) grants 2.7 million share options and 2.7 million restricted share units
Beihai Kangcheng-B (01228.HK) announced that on April 9, 2024, the company granted a total of 2.7 million share purchase rights to two share option grantees under the initial public offering after-sales share option plan and a total of 2.7 million restricted share units to two restricted share unit grantees under the initial public offering post-sale restricted share unit plan.
Zhitong FinanceApr 9 22:00
Beihai Kangcheng-B (01228) announced annual results. Shareholders' losses amounted to 379 million yuan, a year-on-year decrease of 21.64%
Beihai Kangcheng-B (01228) announced results for the year ended December 31, 2023, with revenue of 103 million...
Zhitong FinanceMar 29 00:44
CANBRIDGE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsMar 28 22:00 · Announcements
Beihai Kangcheng-B (01228.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Beihai Kangcheng-B (01228.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve (among other things) the results and announcements of the company and its subsidiaries for the year ended December 31, 2023.
Gelonghui FinanceMar 18 16:56
No Data
No Data